Adaptimmune Data to be Presented in an Oral Presen

PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, today announced that new data will be presented in an oral presentation and a trial in progress poster at the upcoming CTOS meeting that will be held November 8-11 at the Grand Wailea Resort in Hawaii.

Dr. Sandra P. D’Angelo of Memorial Sloan Kettering Cancer Center will be presenting an update on the company’s ongoing study of NY-ESO SPEAR T-cells in synovial Sarcoma. There will also be a trial in progress poster for the ongoing study of NY-ESO SPEAR T-cells in Myxoid/Round Cell Liposarcoma (MRCLS). Details are below:

Oral Presentation:

• Title: Open Label Non-Randomized Multi-Cohort Pilot Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells in HLA-A2 ⁺ Patients with Synovial Sarcoma (NCT01343043)   -  Abstract ID: 2804696   -  Session Title: Symposium 1: Medical, Pediatric and Young Adult Oncology   -  Session Time: November 9, 2017 from 10:30 AM to 12:00 PM   -  Location: Haleakala 1

Trial in Progress Poster:

• Title: A Pilot Study of NY-ESO-1 SPEAR T-Cells in Subjects with Advanced Myxoid/Round Cell Liposarcoma (NCT02992743)   -  Abstract ID: 2804696   -  Presentation time: The poster will be on display throughout the meeting.   -  Poster Session : November 9, 2017 from 5:30 PM to 6:30 PM   -  Location: Haleakala 2 & 3

About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. GlaxoSmithKline plc (LSE: GSK ) (NYSE: GSK ) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 2, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts Investor Relations Juli P. Miller, Ph.D. T: (215) 825-9310 E: juli.miller@adaptimmune.com

Media Relations Margaret Henry T: +44 (0)1235 430036 Cell: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com